These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 19393840)

  • 1. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
    Datto C; Berggren L; Patel JB; Eriksson H
    Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
    Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
    Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
    De Deyn PP; Eriksson H; Svensson H;
    Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
    Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
    Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies.
    Meulien D; Huizar K; Brecher M
    Hum Psychopharmacol; 2010 Mar; 25(2):103-15. PubMed ID: 20196185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
    Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
    J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications.
    Bui K; Earley W; Nyberg S
    Curr Med Res Opin; 2013 Jul; 29(7):813-25. PubMed ID: 23574265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
    Bartkó G
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
    Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
    Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
    Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
    Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.
    Gordi T; Hou E; Kasichayanula S; Berner B
    Clin Ther; 2008 May; 30(5):909-16. PubMed ID: 18555937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.